Abby Hardy, Author at BioTuesdays

Executive Moves

Akcea names Damien Devitt as CEO

Damien Devitt, who has been interim CEO of Akcea Therapeutics (NASDAQ:AKCA) since September 2019, has been promoted to CEO, effective immediately, and will continue to serve as a member of Akcea’s board. “With his...

March 24, 2020

Markets

Mackie Research ups Profound Medical to speculative buy

Mackie Research upgraded Profound Medical (TSX:PRN; NASDAQ:PROF) to “speculative buy” from “hold,” but reduced its price target to $16.20 from $26.10 due to the anticipated impact of the coronavirus. The stock closed at...

March 24, 2020

Markets

Analysts see strong rationale for Hepion CRV431’s use in severe COVID-19 cases

Hepion Pharmaceuticals’ (NASDAQ:HEPA) CRV431, a cyclophilin inhibitor with antifibrotic and antiviral properties, may show some effect in the ongoing COVID-19 pandemic, according to Roth Capital Partners and Brookline...

March 20, 2020

Developments

Dicerna gets FDA orphan drug designation for alpha-1 antitrypsin deficiency drug candidate

Dicerna Pharma (NASDAQ:DRNA) received FDA orphan drug designation for DCR-A1AT for the treatment of alpha-1 antitrypsin deficiency, a genetic disorder that can cause lung and liver disease. The company submitted a...

March 19, 2020

Developments

Soligenix reports positive topline results from Phase 3 cutaneous T-cell lymphoma trial

Soligenix (NASDAQ:SNGX) reported positive topline results for its Phase 3 trial assessing SGX301 for the treatment of cutaneous T-cell lymphoma (CTCL). The study enrolled 169 patients who were randomized to receive...

March 19, 2020

Developments

Abeona treats first patient in Phase 3 VIITAL gene therapy trial

Abeona Therapeutics (NASDAQ:ABEO) treated the first patient in its Phase 3 clinical trial evaluating EB-101 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). The trial, being conducted at Stanford...

March 19, 2020

Developments

Alpine Immune Sciences gets two FDA orphan drug designations for ALPN-101

Alpine Immune Sciences (NASDAQ:ALPN) received two FDA orphan drug designations for ALPN-101 for the prevention and treatment of acute graft-versus-host disease (GvHD). ALPN-101 is a selective dual T-cell co-stimulation...

March 19, 2020

Markets

Raymond James sees Profound Medical insulated from COVID-19 fallout

Raymond James reiterated that Profound Medical (TSX:PRN; NASDAQ:PROF) remains its “analyst current favorite” and “2020 Best Pick,” saying Profound is “particularly insulated from the current economic fallout of COVID-19...

March 12, 2020

Developments

Hepion’s CRV431 shows potential to treat idiopathic pulmonary fibrosis

Hepion Pharmaceuticals (NASDAQ:HEPA) reported positive findings from a translational research study assessing the effects of CRV431 on lung tissue obtained from a patient with idiopathic pulmonary fibrosis (IPF). In the...

March 12, 2020

Developments

Albireo Pharma completes patient enrollment in Phase 2 NASH/NAFLD study

Albireo Pharma (NASDAQ:ALBO) completed patient enrollment in its Phase 2 trial of elobixibat for the treatment of nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD). The trial enrolled 47...

March 10, 2020

Author - Abby Hardy

Akcea names Damien Devitt as CEO

Mackie Research ups Profound Medical to speculative buy

Analysts see strong rationale for Hepion CRV431’s use in severe COVID-19 cases

Dicerna gets FDA orphan drug designation for alpha-1 antitrypsin deficiency drug candidate

Soligenix reports positive topline results from Phase 3 cutaneous T-cell lymphoma trial

Abeona treats first patient in Phase 3 VIITAL gene therapy trial

Alpine Immune Sciences gets two FDA orphan drug designations for ALPN-101

Raymond James sees Profound Medical insulated from COVID-19 fallout

Hepion’s CRV431 shows potential to treat idiopathic pulmonary fibrosis

Albireo Pharma completes patient enrollment in Phase 2 NASH/NAFLD study

Subscribe